Brilliance Tube for Tomorrows Effervescent Tablets
With Brilliance, Sanner GmbH offers an expressive packaging solution for effervescent tablets. Drug producers can achieve higher attention and customer loyalty thanks to photorealistic printing and a wide range of design options. Patients profit from easy handling, while manufacturers can optimise their supply chain while ensuring the highest process safety.
Pain killers and other pharmaceutical agents can be easily digested and consumed in liquid form. Moreover, patients particularly appreciate the easy handling of effervescent tubes. Equipped with a convenience closure like the FOG from Sanner, the tubes remain tightly closed at all times, while the tablets are protected against light and moisture with a long shelf life. In contrast to blisters, for instance, the drugs remain inside their package, which in turn is not damaged during transport.
From a brand point of view, however, this packaging type has been reduced to its mere functionality and can rarely impress with an appealing design. For this reason, Sanner launched the Brilliance Tube last year. Apart from the optimal tablet protection, the development focused on the visual appearance. Compared with conventionally printed packages, the IML tubes offer a high-quality photorealistic printing with endless design varieties. Up to eight colors and metallic effects are available; the shock-proof and scratch-resistant material is extremely durable.
High Recognition Value, Safe Processes
“After the market launch we have already delivered the first Brilliance Tubes with the proven Sanner closures as complete solutions,” says Sanner CEO Holger Frank. “That way, customers can optimise their supply chains and make their daily work easier.” With its GMP-compliant, controlled production, Sanner complies with the highest hygiene standards. Moreover, the patented geometry of the tube base ensures high safety throughout the entire filling and packaging process. “Sanner customers receive everything from a single source — from the procurement of printed labels and manufacturing of decorated tubes to the delivery as system solution. If a customer wants the tubes to be child-resistant, we also have a solution to offer.”
Pharmaceutical manufacturers can bring their sales messages to life by choosing the ideal motif, conveying emotions without many words. They can design a consistent marketing concept with high recognition value — from print and online advertising to TV ads, as well as primary and secondary packaging. The visual messages can easily be transferred from the secondary to the primary packaging, so that patients can see the brand image at all times, either on their table or in the shelf. The excellent readability of the labels offers more room for product information, even on a small surface and with small fonts. This way, Brilliance unites high recognition value at point of sale with optimal consumer convenience and reliable filling processes.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance